In this episode, Alan Minsk, AGG Food & Drug practice chair and Life Sciences co-chair, and Gabe Scannapieco, Litigation and Healthcare partner and Life Sciences co-chair, unpack recent shifts at the U.S. Department of Justice that could reshape regulatory risk for life sciences organizations.

They discuss the disbanding of DOJ’s Consumer Protection Branch ("CPB") and what the loss of centralized oversight could mean for coordinated investigations in the industry. The conversation also examines DOJ’s intensified focus on counterfeit drugs and its targeting of the entire supply chain in collaboration with FDA, DEA, and other agencies.

Drawing on Gabe’s experience as a former assistant director at the CPB and the firm's extensive regulatory services, this episode provides practical insights for companies looking to stay ahead of shifting enforcement priorities.

In this episode, Alan Minsk, AGG Food & Drug practice chair and Life Sciences co-chair, and Brian Stimson, co-chair of the Healthcare practice and former acting general counsel and principal deputy general counsel of the U.S. Department of Health and Human Services ("HHS"), discuss three recent developments affecting life sciences companies.

Alan and Brian review the HHS policy-making process, including the formal requirements for changing policies that have undergone notice-and-comment rulemaking. They also examine the Supreme Court’s decision in Trump v. CASA, which limits nationwide injunctions and places greater responsibility on companies to take direct action to protect their interests. Finally, they address the newly formed DOJ-HHS False Claims Act Working Group, highlighting its enforcement priorities — such as drug and device pricing and kickbacks — and potential implications for payment suspensions and case dismissals.

In this episode, Alan G. Minsk, AGG Food & Drug team leader, and Anuj Desai, AGG Intellectual Property partner and head of Trademarks, discuss recent developments that remind our audience in the food and drug space that FDA is not the only regulatory agency that’s keeping an eye on the marketplace. Alan and Anuj look at how NAD, a BBB program that supports advertising self-regulation, recently addressed a challenge in the prescription drug space. They also talk about how FTC investigative priorities in the past several months may be relevant to the food and drug/life sciences space.